Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Department of Head and Neck/Thoracic Oncology, The First People's Hospital of Foshan, Foshan, China.
Cancer Cell. 2024 May 13;42(5):727-731. doi: 10.1016/j.ccell.2024.04.005. Epub 2024 May 2.
As immunotherapy makes its way into the perioperative setting, a growing number of clinical trials are expanding the evidence base for resectable non-small cell lung cancer (NSCLC) management. Identifying the optimal treatment pattern-whether it's neoadjuvant, adjuvant, or a combination of both-is a crucial next step, particularly in pinpointing which patients benefit the most. This decision-making process requires a multi-disciplinary treatment team capable of utilizing tissue and plasma genomic testing to inform therapeutic choices. Leveraging the perioperative treatment platform, it remains pivotal to integrate circulating tumor DNA (ctDNA) monitoring into clinical trial design efficiently and provide clear guidance on treatment.
随着免疫疗法进入围手术期，越来越多的临床试验正在扩大可切除非小细胞肺癌 (NSCLC) 管理的证据基础。确定最佳治疗模式——无论是新辅助治疗、辅助治疗还是两者的结合——是至关重要的下一步，特别是在确定哪些患者受益最大。这一决策过程需要一个多学科的治疗团队，能够利用组织和血浆基因组检测来为治疗选择提供信息。利用围手术期治疗平台，有效地将循环肿瘤 DNA (ctDNA) 监测纳入临床试验设计并为治疗提供明确指导仍然至关重要。
